Get the Stockscreener App
92.41
1.16%
1.06
After Hours:
93.00
0.59
+0.64%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences director Jeffrey Bluestone sells $620,355 in stock - Investing.com India
Gilead reports high efficacy in HIV prevention trial - Investing.com
Gilead's HIV Prevention Drug Shows 96% Efficacy in Landmark Phase 3 Trial | GILD Stock News - StockTitan
Gilead's Scientific Innovation at the Forefront of Helping End the HIV Epidemic - Gilead Sciences
Lead Gilead researcher highlights need for inclusive clinical trials for HIV - Clinical Trials Arena
Kiltearn Partners LLP Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Gilead Gets $31.8M In Calif. Case Over Counterfeit HIV Drugs - Law360
A Legacy in Liver Disease TreatmentsSponsor ContentGilead - The Atlantic
Gilead awarded $30m over counterfeit HIV drug scheme - Life Sciences Intellectual Property Review
Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More - Yahoo Finance
Principal Street Partners LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic - AccessWire
Gilead Sciences' Breakthrough HIV Prevention Trial Shows Promise in African Women | GILD Stock News - StockTitan
Fmr LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Dai ichi Life Insurance Company Ltd Sells 205,601 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
The Manufacturers Life Insurance Company Sells 260,875 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech - Pharmaceutical Technology
Gilead Sciences acquires HTI vaccine from AELIX - The Pharma Letter
Toward Health Equity Oncology Grant™ – Cancer Funding - Gilead Sciences
Gilead Sciences' SWOT analysis: HIV giant faces growth hurdles as stock wavers - Investing.com
Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Gilead snaps up HIV jab from Barcelona-based research partner - FirstWord Pharma
Gilead buys HIV vaccine from Spanish biotech following success in clinical collab - Fierce Biotech
Price Over Earnings Overview: Gilead Sciences - Benzinga
Harvest Fund Management Co. Ltd Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Cerity Partners LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Zacks Research Weighs in on Gilead Sciences FY2024 Earnings - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Daiwa Securities Group Inc. - MarketBeat
LPL Financial LLC Has $95.36 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Icon Wealth Advisors LLC - MarketBeat
Meridian Wealth Management LLC Invests $3.56 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Eagle Asset Management Inc. Has $17.41 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC - Barchart
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc. - Business Wire
Gilead Announces Layoffs Amid Strong Q3 Performance, HIV Drug Sa - GuruFocus.com
Q3 EPS Estimates for Gilead Sciences Increased by Analyst - MarketBeat
8,154 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Altiora Financial Group LLC - MarketBeat
Charles Schwab Investment Management Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Pacer Advisors Inc. Has $65.53 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Mizuho Securities USA LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Thompson Siegel & Walmsley LLC Buys 43,921 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Commerce Bank Purchases 7,055 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis, GlaxoSmithKline, Janssen Research & Development - Barchart
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $100.00 - MarketBeat
Gilead’s GS-6791 ameliorates arthritis symptoms in mice - BioWorld Online
Intech Investment Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
PNC Financial Services Group Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Position Increased by Natixis Advisors LLC - MarketBeat
Latham & Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Legal Desire News Network
Watkins Advises on Gilead Sciences' US$3.5 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Gilead Sciences (GILD) Announces Issuance of Senior Notes in New Indenture Agreement - GuruFocus.com
Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer - CSRwire.com
Gilead Sciences Issues $3.5 Billion in Senior Notes - Investing.com India
How Gilead Is Driving Global Health Equity And Innovation - Forbes
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by First Horizon Advisors Inc. - MarketBeat
Gilead Science to Report Q3 Earnings: What's in the Cards? - MSN
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Ontario Teachers Pension Plan Board - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Takes $9.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Prospera Financial Services Inc Has $6.59 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Gilead discloses GS-441524 prodrugs for treatment of viral infections - BioWorld Online
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):